Supplement

Ellagic Acid

Ellagic Acid

Evidence TierCWADA NOT PROHIBITED

tuneTypical Dose

200-500 mg/day ellagic acid equivalent, split 1-2 doses with meals.

watchEffect Window

Typical onset is assessed over 1-4 weeks. Clearer signals often emerge by 4-12 weeks.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Ellagic Acid is a plant derived polyphenol or pigment found in many fruits and herbs. It is used for antioxidant support and cardiometabolic research.

Controlled trials with polyphenol rich preparations sometimes show modest improvements in endothelial function, oxidative stress biomarkers, or postprandial glucose. Effects are inconsistent because dose and bioavailability vary. Minority literature explores neuroprotection, skin photoprotection, and microbiome modulation, with evidence mostly preclinical or from small human studies.

Modulation of signaling pathways implicated in the target symptom domain.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • PMID 41656621 and 41599187 show modest endpoint-specific improvements in selected cardiometabolic or inflammatory markers
  • PMID 41172696 and 40926862 report mixed efficacy that depends on extract composition and baseline phenotype

Secondary Outcomes

  • PMID 41656621 and 41599187 report generally acceptable tolerability with mostly mild gastrointestinal events
  • Outcome consistency is stronger when one standardized formulation is used across the full cycle

Safety

Contraindications and Interactions

Contraindications

  • Known allergy to source material
  • Unstable psychiatric states
  • Advanced liver/kidney disease

Side effects

  • Gastrointestinal discomfort
  • Headache
  • Transient fatigue or stimulation depending on formulation

Interactions

  • Sedatives, stimulants, and blood-pressure- or anticoagulant-active medications
  • Overlapping botanicals with similar mechanism burden
  • Multi-ingredient stacks without washout

Avoid if

  • Unmonitored pregnancy/lactation
  • Severe liver/renal injury
  • Recent cardiovascular instability

Evidence

Study-level References

ellagic-acid-SRC-001Human clinical literature (PMID: 41656621; PMID: 41599187)
Sourceopen_in_new

PMID: 41656621,41599187

Population: Adults in condition-specific settings

Dose protocol: Oral ellagic-acid-containing interventions with formulation-specific dosing

Key findings: Modest, context-specific effects

Notes: Small sample sizes, short durations, and nonstandardized endpoints

Paper content

Modest, context-specific effects

ellagic-acid-SRC-002Human evidence synthesis (PMID: 41172696; PMID: 40926862)
Sourceopen_in_new

PMID: 41172696,40926862

Population: Adult cohorts across variable indications

Dose protocol: Mixed products/doses

Key findings: Heterogeneous or inconsistent pooled outcomes

Notes: Publication and comparability limitations

Paper content

Heterogeneous or inconsistent pooled outcomes

ellagic-acid-SRC-003Randomized, double-blind, parallel-group, placebo-controlled trial.
Sourceopen_in_new

Jafari T, Fallah AA, Reyhanian A, Sarmast E. Effects of pomegranate peel extract and vitamin E on the inflammatory status and endothelial function in hemodialysis patients: a randomized controlled clinical trial. Food Funct. 2020;11(9):7987-7993. doi:10.1039/d0fo01012j. PMID:32839797.

Population: Hemodialysis patients with end-stage renal disease.

Dose protocol: Pomegranate peel extract (90 mg ellagic acid) with or without vitamin E for 8 weeks in hemodialysis patients

Key findings: Combined treatment significantly reduced CRP (-7.12 mg/L), IL-6, TNF-alpha, ICAM-1, and VCAM-1 versus placebo.

Notes: 100 participants, double-blind. Combination design limits attribution to ellagic acid alone. Population with high baseline inflammation.

Paper content

This double-blind RCT tested pomegranate peel extract (containing 90 mg ellagic acid) with or without vitamin E in 100 hemodialysis patients over 8 weeks. The combination treatment significantly reduced CRP (mean change -7.12 mg/L), IL-6, TNF-alpha, ICAM-1, and VCAM-1 compared to placebo. Both single interventions also reduced CRP versus placebo. P-selectin showed no significant changes. The study provides human evidence for the anti-inflammatory effects of ellagic acid-rich pomegranate extract in a population with elevated baseline inflammation, though the combination design makes it difficult to attribute all benefit to ellagic acid alone.

ellagic-acid-SRC-004Randomized crossover trial.
Sourceopen_in_new

Long J, Guo Y, Yang J, et al. Bioavailability and bioactivity of free ellagic acid compared to pomegranate juice. Food Funct. 2019;10(10):6582-6588. doi:10.1039/c9fo01683j. PMID:31552981.

Population: Healthy adult volunteers.

Dose protocol: 500 mg pure ellagic acid versus 237 mL pomegranate juice (120 mg ellagic acid) in crossover design

Key findings: Both sources achieved equivalent plasma ellagic acid levels, but pomegranate juice showed superior anti-inflammatory bioactivity (lowered MCP1).

Notes: Suggests whole-food matrix contributes bioactivity beyond isolated ellagic acid.

Paper content

This randomized crossover trial compared 500 mg of pure ellagic acid to 237 mL of pomegranate juice (containing roughly 120 mg ellagic acid) in healthy volunteers. Both sources achieved equivalent plasma ellagic acid levels, but pomegranate juice produced greater phase II metabolism and reduced the inflammatory marker MCP1, while pure ellagic acid did not. The findings suggest that other constituents in pomegranate juice contribute to the anti-inflammatory bioactivity beyond ellagic acid alone, which is relevant for understanding whether isolated ellagic acid supplements fully replicate the benefits of whole-food sources.

Guides

Setup

Help